Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
A Phase II study of temsirolimus in combination with standard chemotherapy (irinotecan;
cyclophosphamide, doxorubicin and etoposide (CAE); cisplatin and etoposide (HiPE) and
topotecan (TPT) followed by and additional six courses of induction chemotherapy and then
intensification with autologous hematopoietic stem cell transplantation. The first five
courses of induction chemotherapy will also evaluate the feasibility of combining weekly
temsirolimus with these standard chemotherapy combinations. This will be followed by 16
months of oral maintenance therapy with eight months of 13-cis-retinoic acid and then eight
months of oral topotecan.